44 results about "Carcinoma bladder" patented technology

The invention provides methods of detecting cancerous cells in biological samples using a double staining / dual imaging approach, which can be used to diagnose cancer. More specifically, the present invention provides methods of diagnosing bladder cancer by a simultaneous scanning of cell morphology and FISH signals of cells derived from a urine sample.

The invention provides an integrated detection method for separating, enriching and detecting an exosome. The method comprises the following steps: designing and assembling a dual-membrane filtration chip, constructing an ELISA detection standard curve, collecting a sample, injecting and washing, performing chip ELISA detection, and performing data processing analysis. The invention also provides an integrated detection chip for separating, enriching and detecting a urine exosome. A reaction system and the detection method of the present invention can be used for detecting the content of a urine sample of a bladder cancer patient and the exosome in a supernatant of a bladder cancer cell line nutrient solution. The detection chip has characteristic of high specificity, generates no influence or wound on human body, and the detection method does not require the expensive precision experiment apparatus (such as an ultra centrifuge and a fluorescence microscope), and has large application prospect.

The invention discloses two halogenated 8-hydroxyquinoline platinum (II) complexes and a synthesis method and application thereof. The structures of the halogenated 8-hydroxyquinoline platinum (II) complexes are shown in the formula (I), and the synthesis method comprises the steps that an 8-hydroxyquinoline derivative and dichloro bis(dimethyl sulfoxide) platinum are taken and subjected to a coordination reaction in a polar solvent, and the halogenated 8-hydroxyquinoline platinum (II) complexes are obtained. It is shown through experiments carried out by an applicant that the halogenated 8-hydroxyquinoline platinum (II) complexes have good activity of inhibiting the proliferation of certain tumor cell strains and can selectively inhibit the growth of bladder cancer T-24 cells, and the apoptosis of the tumor cells is induced under the function of targetedly interfering with mitochondria; meanwhile, the toxicity of the complexes to human normal cells HL-7702 is low. The structures of the halogenated 8-hydroxyquinoline platinum (II) complexes and the structure of the 8-hydroxyquinoline derivative are shown in the following formulas (I) and (II) respectively, wherein the formulas (I)and (II) are shown in the description, and R1 represents Cl or Br.

The invention relates to a method for preparing the extract of corchorus capsularis seeds and the application of the extract. According to the method, corchorus capsularis seeds are crushed, and the petroleum ether 5 times the weight of corchorus capsularis seeds is added at the room temperature for extracting and degreasing. After the degreasing process, corchorus capsularis seeds are subjected to reflux extraction for 1-3 times in the ethanol aqueous solution 5-10 times the weight thereof, and the reflux extraction process lasts for 1-3 hours each time. The obtained extract is collected as the ethanol extract of corchorus capsularis seeds and is stored at 20 DEG C. The extract can be used for inhibiting the cell proliferation of human bladder cancer cells. Compared with the prior art, the extract is more efficient in growth proliferation effect for the human bladder cancer cell line T24 and has less influence on normal bladder epithelial cells. Therefore, the extract has an important significance on the treatment of bladder cancers, the comprehensive utilization of corchorus capsularis seed resources in China, and the increment of incomes for corchorus capsularis growers.

The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.

The invention discloses application of a pharmaceutical composition in preparation of a therapeutic drug for a tumor insensitive to PD-1 antibody immunotherapy, and particularly relates to applicationof a PD-1 antibody combined LY2874455 in preparation of a drug for treating a chromosome 11q13.3 segment amplified tumor. Advanced solid tumors include esophageal squamous carcinoma, colorectal cancer, melanoma, head and neck squamous carcinoma or bladder cancer and the like. The anti-PD-1 antibody and LY2874455 combined medication scheme can be used for the tumor which is amplified in the chromosome 11q13.3 segment and is insensitive to PD-1 antibody immunotherapy, and compared with single-drug treatment, tumor growth is remarkably inhibited, so that a patient ineffective to the PD-1 antibody can benefit from the combined therapy.

The present invention discloses a cancer-treating toad venom targeted liposome and a preparation method and application thereof. The toad venom targeted liposome includes a targeted site carbonic anhydrase CA9 antibody, a liposome and toad venom. The liposome covers the toad venom, and then is connected with the carbonic anhydrase CA9 antibody, so that the toad venom targeted liposome can specifically act on CA9 overexpressing cancer cells for targeted killing of the cancer cells. Results of studies on characteristics of the prepared toad venom targeted liposome, tumor cell MTT experiments and in-vivo pharmacodynamic experiments show that the toad venom targeted liposome is relatively stable, difficult to gather, good in targeting property and high in therapeutic index. The toad venom targeted liposome is useful in the treatment of colon cancer, bladder cancer, renal cancer, cervical cancer, brain glioma and gastric cancer.

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

The invention provides a single-stranded antibody fusion protein in growth factor receptors of human fibroblast cells. The single-stranded antibody fusion protein is an FGFR single-stranded antibody-alkaline polypeptide fusion protein, wherein the FGFR single-stranded antibody is the single-stranded antibody of FGFR1, 2, 3 or 4; and alkaline polypeptide is a polypeptide which comprises 9 to 30 alkaline amino acids. The invention further provides the application of the FGFR single-stranded antibody-alkaline polypeptide fusion protein in preparing targeting tumor cells medicines. In the application, the fusion protein is used as nucleic acid carriers to carry micro-molecules to disturb RNA (such as siRNA) to attack various tumor cells and tissues (such as leukemia stem cell, bladder cancer cell, breast cancer cell and the like) with high expression of FGFR correspondingly; and by inducing the tumor cells to die, restraining the growth and the division of the tumor cells and the like, the growth, the attack and the transference of the tumor cells are restrained at last.

The invention discloses a preparation method and application of a magnetic structural color hydrogel microcarrier for bladder cancer protein multi-element analysis, and the method comprises the following steps: by using a silicon dioxide photonic crystal microstructure as a template, filling hydrogel with excellent mechanical properties in nano particle pores, curing, and removing the template toobtain a microcarrier with an inverse opal structure; and preparing functional pre-gel mixed with magnetic nanoparticles, pouring the functional pre-gel into gaps of the inverse opal structure, and carrying out ultraviolet polymerization to obtain the periodically ordered magnetic structure color hydrogel microcarrier similar to the template. The preparation method has the advantages of low preparation cost, good repeatability, simple operation and the like, and the prepared magnetic structural color hydrogel microcarrier has the characteristics of non-specific protein binding resistance, supply of a probe coupling active group, directional magnetic control effect and the like, has the properties of good coding stability, high flexibility and the like of a liquid phase chip, and also hasthe performance advantages of high sensitivity and high specificity when being used for multielement analysis of bladder cancer protein.

The invention discloses an artemisinin derivative, a synthesis method and applications thereof. The artemisinin derivate is N-(3-N',N'-dimethylamino-propyl)-10-azadeoxyartemisinin, which is prepared by reacting artemisinin with N,N-dimethyl-1,3-diaminopropane and p-toluene sulfonic acid in sequence. By researching the proliferation inhibition activity of the derivative on multiple human tumor cell strains and human normal cell strains, the applicant finds that the derivative has a prominent proliferation inhibition activity on human bladder cancer cell T-24, human ovarian cancer cell SK-OV-3, and human stomach cancer cell MGC80-3, has a potential medicinal value, and can be used to prepare various antitumor drugs.

The invention discloses a newly discovered cancer promoting effect of DDX24 helicase, a method for realizing a cancer inhibition effect through point mutation and application of the DDX24 helicase. The contents of the invention comprise: 1, high expression of wild type DDX24 has significant correlation with tumor growth, and the growth of tumors can be promoted through high expression of the wildtype DDX24; 2, different from the mechanism of the pathogenic gene DDX24 for familial vascular malformation, DDX24 point mutation including K11E or E271K obviously inhibits the growth of tumors; 3, based on the new function and induced point mutation of DDX24 provided in the invention, a novel targeted therapy method can be provided for treatment of latent and refractory tumors, and a new thoughtcan also be provided for preparation of tumor-related vaccines; and 4, application of 1-3 described above is provided. The point mutation can be used for treating solid tumors including, but not limited to, squamous cell carcinoma of the head and the neck, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, skin melanoma, lymphoma, adenoma, thoracic adenoma, lung cancer, colorectal cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, nasopharyngeal cancer, bone cancer andmalignant myoma.

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

The invention belongs to the field of gene engineering, particularly relates to a protein sequence capable of efficiently inhibiting malignant tumors, and further relates to a gene sequence for encoding the protein sequence and application of the protein sequence. The application of the protein sequence as shown in SEQ ID NO.1 in preparation of a preparation for inhibiting the malignant tumors isthe key protected content of the invention. The protein sequence as shown in SEQ ID NO.1 is expressed by a gene sequence as shown in SEQ ID NO.2; and in addition, the gene sequence as shown in SEQ IDNO.2 is also the protected content of the invention. The protein sequence provided by the invention has the following advantages that the protein sequence has an excellent inhibition function in various tumor cells of bladder cancer, lung cancer and the like; the cancer inhibition effect is quick and obvious; and besides, the sequence provided by the invention is a human-derived sequence, does notcause rejection reaction, and has a wide application prospect.

The present invention relates to a method for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter. The method uses reaction compositions that comprise amplification primers and genotyping probes. Another aspect of this invention relates to the primers and probes used to implement the aforementioned method, with sequences, identified as SEQ ID no.1 to SEQ ID no.6, that displayhigh specificity for these mutations, and to the compositions containing these primers and probes. The present invention further relates to a kit comprising the above-mentioned compositions for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter by carrying out the method according to the present invention. The method, gene sequences, compositions and kit of the present invention can be advantageously used for detecting trace amounts of c.-124 C>T and c.-146 C>T mutations in biological samples, due to their high sensitivity and specificity for such mutations. The present invention can thus be applied in early detection, identification, detection of recurrence or prediction and monitoring of diseases associated with this type of mutations, such as bladder carcinomas, thyroid carcinomas, squamous cell carcinomas, basal cell carcinomas, melanomas, gliomas and hepatocellular carcinomas, inter alia, and ultimately provide the basis for defining a suitable treatment. Thus, the present invention pertains to the technical fields of medicine, pharmaceutics, molecular biology, biochemistry, human genetics and the like.

The present invention refers to a method for the detection of the c.-124 C>T and c.-146 C>T mutations in Htert gene promoter. The referred method uses a reaction composition that comprises primers for amplification and probes for genotyping.Another aspect of this invention refers the primers and probes used in performing the aforementioned method with sequences, identified as SEQ ID nr.1 to SEQ ID nr.6, that display high specificity for these mutations, as well as compositions that contain them.The present invention further refers to a kit comprising the above mentioned compositions for detecting mutations c.-124 C>T and c.-146 C>T mutations in Htert gene promoter by conducting the present method invention.The method, gene sequences, compositions and kit of the present invention can be advantageously used for detecting trace amounts of c.-124 C>T and c.-146 C>T mutations, present in biological samples due to its high sensitivity and specificity for such mutations.The present invention can therefore be applied in early detection, identification, detection of recurrence or prediction and monitoring of diseases associated with those mutations, such as bladder carcinomas, thyroid carcinomas, squamous cell carcinoma, basal cell carcinomas, skin cancer, central nervous system cancers and hepatocellular carcinoma, among others and eventually provide the basis for appropriate treatment setting.Thus, the present invention falls within the technical field of medicine, pharmaceutics, molecular biology, biochemistry, and human related genetics.

The invention belongs to the technical field of medicines, and particularly relates to a method for detecting immunologic characteristics of primary tumor cells. The in-vitro detection method for the immunologic characteristics of the primary tumor cells comprises the following steps: culturing the primary tumor cells from different patient sources, establishing a bladder cancer primary tumor cell bank, detecting the expression level of PD-L1 before and after the primary cell IFN-gamma stimulation through a high-throughput flow detection platform, incubating the primary cells and the recombinant human PD-1-Fc chimeric protein, and detecting the binding capacity of the primary cells to the PD-1 protein. The immunotherapy effect of the corresponding patient is predicted in combination with the series of indexes. According to the invention, a convenient primary cell culture method and a high-throughput flow detection platform are utilized, and the individual prognosis evaluation of the in-vitro platform on cancer patients is realized by dynamically, quickly, accurately and quantitatively detecting the immune-related protein expression level and the in-vitro binding capacity of primary tumor cells.

A device for selective capture of target bladder cancer cells from urine or a urine derived fluid is provided. The device comprises a substrate having one or more cell capture surfaces, each cell capture surface comprising a functionalized film on the substrate and one or more target bladder cancer cell selective binding agents covalently bound to the functionalized film.

The invention relates to a group six dim carbocyclic ring azoles nucleoside analogues and their acceptable pharmaceutical compounds and their preparation methods and the application as antiviral and antineoplastic agents.The described compounds have varying degrees of inhibition effects on the human immunodeficiency virus replication and the replication of herpes virus; have varying degrees of inhibition on human lung cancer cell lines and human bladder cancer cell lines.

The invention discloses a novel application of a synthetic fiber-like serpentine nano material (SCNT), and particularly relates to an application of the synthetic fiber-like serpentine nano material as a circPRMT5 siRNA carrying material in the aspect of cancer treatment, and further, specific cancer is bladder cancer. According to the invention, a carrier is the synthetic fiber-like serpentine nano material, and siRNA of circular RNA is carried. Experimental results show that the synthetic fiber-like serpentine nano material carrying circPRMT5 siRNA has a good targeting effect on circPRMT5 high-expression bladder cancer cells and tissues, and besides, the synthetic fiber-like serpentine nano material can inhibit growth and metastasis of tumors.

The invention provides an immune-enhancing antineoplastic collagen composition as well as a preparation method and an application thereof. The composition is characterized by consisting of antineoplastic factors, collagen, polysaccharide substances and active factors. The composition is applicable to, but not limited in, cells for treating breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostatic cancer, bladder cancer, melanoma, lung cancer, stomach cancer, liver cancer, head and neck squamous cell carcinoma, carcinoma of uterine cervix, renal cell carcinoma, thyroid cancer, acute myeloid leukemia, myeloma, esophageal squamous cancer, lymphoma and the like.

The invention provides a lentivirus-infected human bladder cancer cell line to knock out endogenous genes, and successfully establish a stable transfection cell line. Specifically, NPM1‑shRNA lentivirus infected T24 / DDP cell line to silence NPM1 (nucleolar phosphoprotein 1) expression, and successfully established T24 / DDP‑NPM1 ko cell line. The present invention confirms T24 / DDP-NPM1 through research ko Cell lines can be stably silenced NPM1 expression and passaged. T24 / DDP‑NPM1 after silencing NMP1 compared to negative control ko The expression level of NPM1 protein in the cell line was significantly decreased, the cell proliferation ability was significantly inhibited, the cell migration ability was increased, and the cell cycle was arrested in the S phase.

The invention provides a polygene combined methylation detection method and application thereof, and the method comprises the following steps: step 1): carrying out first PCR amplification on a DNA sample treated by hydrosulfite to obtain a target template DNA fragment; 2) carrying out PCR amplification on the target template DNA fragment obtained in the step 1) for the second time, and carrying out biotin labeling on a methylation sequence in the DNA fragment; 3) hybridizing the PCR product labeled by biotin in the step 2) with a label complementary sequence on the hybridized magnetic bead, and carrying out fluorescence labeling by using a fluorescent dye; and 4) detecting the fluorescence labeled product obtained in the step 3), and judging the methylation condition of the target gene in the DNA sample. A plurality of methylated DNA samples can be amplified, a PCR product is hybridized with different magnetic bead complementary tag sequences, the gene methylation condition is determined through a fluorescence labeling product, and the whole detection process is rapid and high in accuracy; and the detection method is widely applied to early screening of canceration genes of diseases such as colon straight cancer, bladder cancer and cervical cancer.

The invention relates to a group six dim carbocyclic ring azoles nucleoside analogues and their acceptable pharmaceutical compounds and their preparation methods and the application as antiviral and antineoplastic agents.The described compounds have varying degrees of inhibition effects on the human immunodeficiency virus replication and the replication of herpes virus; have varying degrees of inhibition on human lung cancer cell lines and human bladder cancer cell lines.

The present invention discloses a DC-CIK co-cultured cell, a preparation method thereof, a sensitizing antigen and an application thereof. The DC-CIK co-cultured cell is prepared by using separated mononuclear cells to be respectively induced and cultured into DC cells and CIK cells, wherein the DC cells are induced and stimulated by adding a self-constructed polypeptide sensitizing antigen whichis proven to be widely expressed in various tumor cells during a culture process, which can improve tumor killing effects. The DC-CIK co-cultured cell cultured by the method can have a very good killing effect on a variety of the tumor cells. Besides, the cultured DC-CIK cells have high activity and strong amplification ability, releases many cytokines of IFN-gamma, etc., and is strong in lethality. The co-cultured cell can be widely used in treatment of various cancers, including kidney cancers, prostate cancers, breast cancers, bladder cancers, melanoma, colon cancers, ovarian cancers, bonecancers, lung cancers, neuroblastoma, etc., and is wide in adaptive surfaces.

This disclosure is in the field of cancer immunotherapy and relates to all cancer types, including but not limited to cancers of the breast, lung, prostate, pancreas, colon, bladder, brain, head-neck, kidney, esophagus, skin, and blood cells. The embodiments provide methods for selecting and amplifying specific targeting molecules to use in therapy and diagnostic testing. Targets include but are not necessarily limited to architecturally preserved, usually heterogeneous specific surface structures present on individual cancer cells and cancer stem cells but not on non-malignant cells. The embodiments are novel in that they provide these binding molecules for one individual's cancer regardless of the rarity of an individual cancer cell or stem cell and promptly enough to initiate treatment without requiring lengthy immunization or hybridoma production that are current art.

The invention discloses application of argyreia aceta alkali in biological medicines. The whole herb of argyreia aceta has medicinal value, and argyreia aceta is widely distributed in many places of Guangxi, such as Guigang, Yulin, Fangcheng Gang and Wuming, and is used as a traditional Chinese medicine for treating acute and chronic bronchitis, tuberculosis, liver cirrhosis, nephritis edema, sores and furuncles, acute mastitis, skin eczema, traumatic bleeding and other symptoms. The argyreia aceta alkali is a chemical component separated from argyreia aceta. According to the invention, through the tests for the proliferation inhibition effect of the argyreia aceta alkali on human lung adenocarcinoma cell H2228, human bladder cancer cell T24, human hepatoma carcinoma cell SMMC-7721, humanbreast cancer cell MCF-7, human gastric carcinoma cell MGC-803 and human oral squamous cell carcinoma Tca8113, the argyreia aceta alkali is found to have an excellent inhibiting effect on human bladder cancer cell T24 and human oral squamous cell carcinoma Tca8113 and has no obvious inhibiting effect on other tested tumor cells, so that the argyreia aceta alkali can be used for preparing drugs fortreating bladder cancer or oral squamous cell carcinoma.

The present invention provides a kind of no-cell Calmette-Guerin bacillus preparation, and medicine composition or mucosa immune regulator including the preparation. The no-cell Calmette-Guerin bacillus preparation is prepared through crushing and cracking Calmette-Guerin bacillus in a homogenating crushing process or ultrasonic crushing process. The preparation can strengthen immunological function of normal body, promote restoring of immunological function in hypoimmunity body and inhibit excessive immune response in hyperimmunity body, and has bidirectional immunological regulation. The preparation has obvious tumor inhibiting effect, can prevent cancers, and is one kind of safe and effective mucosa immune regulator.

The present invention relates to a novel regulatory T cell protein. The protein, named PD‑L3ORVISTA, resembles members of the PD‑L1 family and represents a novel and structurally distinct Ig superfamily inhibitory ligand whose ectodomain has the same identity as the B7 family ligand PD‑L1. source. This molecule is called PD‑L3OR VISTA or V-domain immunoglobulin inhibitor of T-cell activation (VISTA). The expression of VISTA is mainly localized in the hematopoietic compartment and is highly regulated on bone marrow APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway suggests a new approach to modulate T cell-mediated immunity for the treatment of various cancers such as ovarian, bladder and melanoma. Additionally, VISTA proteins, particularly multimeric VISTA proteins and antibodies are useful for suppressing T cell immunity in autoimmune diseases, allergies, infections and inflammatory disorders such as multiple sclerosis and joint disorders such as RA.